National Institute on Drug Abuse - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH223330D
- Pages: 51
- November 2018
- Total Views:1132
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
National Institute on Drug Abuse (NIDA), a subsidiary of National Institutes of Health is a research institute that provides drug abuse and addiction services. The institute offers services in drugs of abuse such as bath salts, cocaine, heroin, inhalants, alcohol, club drugs, methamphetamine, prescription drugs, commonly abused drugs, emerging trends, salvia, and tobacco addiction, among others. It also offers services in addiction science, drug testing, drugged driving, global health, hepatitis, comorbidity, criminal justice and drug abuse areas. The institute operates AIDS research program, international program, and intramural research program, among others. NIDA is headquartered in Bethesda, Maryland, the US.
National Institute on Drug Abuse-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Drug Abuse, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 11
Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 12
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 13
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 14
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 15
Licensing Agreements 16
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 16
EncepHeal Therapeutics Enters into Licensing Agreement with National Institute on Drug Abuse 17
National Institute on Drug Abuse-Key Competitors 18
National Institute on Drug Abuse-Key Employees 19
National Institute on Drug Abuse-Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Government and Public Interest 21
Oct 31, 2018: Columbia University receives National Institute on Drug Abuse (NIDA) research grant to study impact of medical cannabis on opioid use in collaboration with Columbia Care 21
Sep 24, 2018: MEBIAS Discovery receives grant from NIDA 22
Sep 17, 2018: Ensysce Biosciences receives multi-year NIDA grant to study and deliver opioid overdose protection 23
Jul 24, 2018: NIH expands program that conducts large-scale clinical trials in real-world settings 24
Jul 09, 2018: Study casts doubt on effectiveness of e-cigs for smoking cessation 25
Jun 28, 2018: New clinician screening tool available for substance use 26
Jun 22, 2018: Analysis of insurance coverage for back pain shows missed opportunities to prescribe non-opioid medications 27
Jun 22, 2018: UCLA receives USD 9.5 million grant to study link between substance use and HIV transmission 28
Jun 19, 2018: Methadone and buprenorphine reduce risk of death after opioid overdose 29
Mar 28, 2018: Study changes long-held concepts of cell decoding 30
Nov 01, 2017: Understanding Addiction in the Adolescent Mind 31
Sep 27, 2017: NIH announces centers for myalgic encephalomyelitis/chronic fatigue syndrome research 33
Sep 27, 2017: Camino Pharma Co-founder Receives USD 10.8 Million Grant for Development of Potential Drug for Cocaine and Nicotine Addiction 35
Sep 26, 2017: UAMS Neuroscientist Receives Grant to Study Resilience of Brain to Mental Illness 36
Sep 15, 2017: Immune System Linked to Alcohol Drinking Behaviour 37
Sep 05, 2017: Treatment for Opioid or Alcohol Abuse Can Be Successful in Primary Care Settings 39
Aug 01, 2017: Collins, King Announce USD 185,413 in Funding to the University of New England to Support Addiction Research 41
Apr 19, 2017: EncepHeal Therapeutics Receives USD 300,000 Grant. 42
Apr 19, 2017: EncepHeal Therapeutics Receives USD 150,000 Notice of Award from the North Carolina Biotechnology Center. 43
Apr 05, 2017: NIDA announces recipients of 2017 Avant-Garde Awards for HIV/AIDS research 44
Jan 30, 2017: New TSRI Study Shows Early Brain Changes in Fragile X Syndrome 46
Product News 47
Dec 20, 2017: Seven Emmes Employees Recognized in Lancet Study Comparing Two Opioid Treatments 47
Other Significant Developments 48
Aug 31, 2018: Novel intervention halves rate of death among people living with HIV who inject drugs 48
Aug 22, 2018: US government orders 3.6 million SPECTRUM research cigarettes from 22nd Century 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51
List Of Figure
List of Figures
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Key Facts 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Drug Abuse, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Drug Abuse, Deals By Therapy Area, 2012 to YTD 2018 9
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 11
Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 12
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 13
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 14
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 15
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 16
EncepHeal Therapeutics Enters into Licensing Agreement with National Institute on Drug Abuse 17
National Institute on Drug Abuse, Key Competitors 18
National Institute on Drug Abuse, Key Employees 19
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
National Institute on Drug Abuse, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
National Institute on Drug Abuse (NIDA), a subsidiary of National Institutes of Health is a research institute that provides drug abuse and addiction services. The institute offers services in drugs of abuse such as bath salts, cocaine, heroin, inhalants, alcohol, club drugs, methamphetamine, prescription drugs, commonly abused drugs, emerging trends, salvia, and tobacco addiction, among others. It also offers services in addiction science, drug testing, drugged driving, global health, hepatitis, comorbidity, criminal justice and drug abuse areas. The institute operates AIDS research program, international program, and intramural research program, among others. NIDA is headquartered in Bethesda, Maryland, the US.
National Institute on Drug Abuse-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Drug Abuse, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 11
Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 12
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 13
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 14
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 15
Licensing Agreements 16
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 16
EncepHeal Therapeutics Enters into Licensing Agreement with National Institute on Drug Abuse 17
National Institute on Drug Abuse-Key Competitors 18
National Institute on Drug Abuse-Key Employees 19
National Institute on Drug Abuse-Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Government and Public Interest 21
Oct 31, 2018: Columbia University receives National Institute on Drug Abuse (NIDA) research grant to study impact of medical cannabis on opioid use in collaboration with Columbia Care 21
Sep 24, 2018: MEBIAS Discovery receives grant from NIDA 22
Sep 17, 2018: Ensysce Biosciences receives multi-year NIDA grant to study and deliver opioid overdose protection 23
Jul 24, 2018: NIH expands program that conducts large-scale clinical trials in real-world settings 24
Jul 09, 2018: Study casts doubt on effectiveness of e-cigs for smoking cessation 25
Jun 28, 2018: New clinician screening tool available for substance use 26
Jun 22, 2018: Analysis of insurance coverage for back pain shows missed opportunities to prescribe non-opioid medications 27
Jun 22, 2018: UCLA receives USD 9.5 million grant to study link between substance use and HIV transmission 28
Jun 19, 2018: Methadone and buprenorphine reduce risk of death after opioid overdose 29
Mar 28, 2018: Study changes long-held concepts of cell decoding 30
Nov 01, 2017: Understanding Addiction in the Adolescent Mind 31
Sep 27, 2017: NIH announces centers for myalgic encephalomyelitis/chronic fatigue syndrome research 33
Sep 27, 2017: Camino Pharma Co-founder Receives USD 10.8 Million Grant for Development of Potential Drug for Cocaine and Nicotine Addiction 35
Sep 26, 2017: UAMS Neuroscientist Receives Grant to Study Resilience of Brain to Mental Illness 36
Sep 15, 2017: Immune System Linked to Alcohol Drinking Behaviour 37
Sep 05, 2017: Treatment for Opioid or Alcohol Abuse Can Be Successful in Primary Care Settings 39
Aug 01, 2017: Collins, King Announce USD 185,413 in Funding to the University of New England to Support Addiction Research 41
Apr 19, 2017: EncepHeal Therapeutics Receives USD 300,000 Grant. 42
Apr 19, 2017: EncepHeal Therapeutics Receives USD 150,000 Notice of Award from the North Carolina Biotechnology Center. 43
Apr 05, 2017: NIDA announces recipients of 2017 Avant-Garde Awards for HIV/AIDS research 44
Jan 30, 2017: New TSRI Study Shows Early Brain Changes in Fragile X Syndrome 46
Product News 47
Dec 20, 2017: Seven Emmes Employees Recognized in Lancet Study Comparing Two Opioid Treatments 47
Other Significant Developments 48
Aug 31, 2018: Novel intervention halves rate of death among people living with HIV who inject drugs 48
Aug 22, 2018: US government orders 3.6 million SPECTRUM research cigarettes from 22nd Century 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51
List Of Figure
List of Figures
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Key Facts 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Drug Abuse, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Drug Abuse, Deals By Therapy Area, 2012 to YTD 2018 9
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 11
Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 12
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 13
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 14
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 15
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 16
EncepHeal Therapeutics Enters into Licensing Agreement with National Institute on Drug Abuse 17
National Institute on Drug Abuse, Key Competitors 18
National Institute on Drug Abuse, Key Employees 19
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
National Institute on Drug Abuse, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
March 2021
Page 140 | November 2020
Page 99 | July 2020
Page 75 | July 2020
Page 114 | May 2020